BIIBNEUTRAL

Revenue Growth (YoY)

1.9%

Higher than 33% of Healthcare sector peers

Updated 654h ago

Sector Performance

33th percentile

BIIB

1.9%

Sector Median

6.2%

Sector Avg

4.2%

📊

Deep Analysis

Biogen’s current Revenue Growth (YoY) of 1.9% measures how much the company’s sales have increased compared to the same quarter last year; for a non-expert investor, this indicates that revenue is barely growing.

This figure sits well below the sector median of 6.2%, placing Biogen in the 34th percentile among its healthcare peers – meaning two-thirds of competitors grew faster. The trend direction is not available (N/A), as the year-over-year change and quarter-over-quarter change are both listed as N/A, providing no insight into recent momentum. With a low revenue-growth level and no trend data to suggest improvement or deterioration, the investment risk is elevated because the company lacks both current growth and a visible trajectory. This metric directly contradicts a bullish outlook but aligns with the overall NEUTRAL verdict: the minimal growth and lack of trend neither strongly support buying nor selling the stock, reinforcing a hold perspective.

Frequently Asked Questions

What does the Revenue Growth (YoY) tell investors about BIIB?

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

How is the Revenue Growth (YoY) calculated?

Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.

How does BIIB's Revenue Growth (YoY) compare to its sector?

BIIB's Revenue Growth (YoY) of 1.9% compares to a Healthcare sector median of 6.2%, placing it in the 33th percentile.

Who are BIIB's closest peers by Revenue Growth (YoY)?

The closest Healthcare peers by Revenue Growth (YoY) include: ALGN (6.2%), AMGN (5.8%), CPRX (5.6%), ABT (7.8%), ZBH (9.3%).

The Formula

(Revenue_t - Revenue_t-4) / Revenue_t-4

Why It Matters

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.